Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568557 | 0.85 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL29703081 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL574252 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| Benzothiophene SCHEMBL28779469 | 0.81 | CA1 (0.42) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL14141472 | 0.79 | CYP1A1 (0.36) | SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A | |
| SCHEMBL97520 | 0.79 | CYP2A6 (0.37) | SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A | |
| SCHEMBL28744575 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL9581565 | 0.74 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CA1CA2 | |
| SCHEMBL6725691 | 0.72 | SIGMAR1 (0.32) | SLC6A2SLC6A4SLC6A3DYRK1A | |
| SCHEMBL29489119 | 0.71 | CYP2A6 (0.54) | SLC6A2SLC6A4SLC6A3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026345-A1 | THIAZOLIDINONE COMPOUNDS, AND METHODS OF MAKING AND USING SAME | TARGEGEN INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-0712404-B1 | BENZOTHIOPHENE ANALOGS AS ANTIVIRAL AGENTS | STANFORD RES INST INT (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0712404-A1 | NOVEL BENZOTHIOPHENE ANALOGS AS ANTIVIRAL AGENTS | STANFORD RES INST INT (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5424315-A | Treating herpes viral infections, particularly cytomegalovirus | SRI INTERNATIONAL (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1995004059-A1 | NOVEL BENZOTHIOPHENE ANALOGS AS ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1995-02-09 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | SLC6A2 3686/4885SLC6A4 3747/4885SLC6A3 4015/4885 |
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | SLC6A2 660/4885SLC6A4 917/4885SLC6A3 594/4885 |
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | SULT1E1, TPMT, SULT1A1 | SLC6A2 863/4885SLC6A4 283/4885SLC6A3 177/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | SLC6A2 2418/4885SLC6A4 1958/4885SLC6A3 3425/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | SLC6A2 3686/4885SLC6A4 3747/4885SLC6A3 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.